
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-manuscript.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F3920500003380DF103B5E.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="nihpa" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC6279493/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279493/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Molecular cancer therapeutics" /><meta name="citation_title" content="Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes" /><meta name="citation_author" content="Marc Payton" /><meta name="citation_author_institution" content="Amgen Discovery Research, Thousand Oaks, California" /><meta name="citation_author" content="Hung-Kam Cheung" /><meta name="citation_author_institution" content="Amgen Medical Sciences, Thousand Oaks, California" /><meta name="citation_author" content="Maria Stefania S. Ninniri" /><meta name="citation_author_institution" content="Amgen Discovery Research, Thousand Oaks, California" /><meta name="citation_author" content="Christian Marinaccio" /><meta name="citation_author_institution" content="Division of Hematology/Oncology, Northwestern University, Chicago, Illinois." /><meta name="citation_author" content="William C. Wayne" /><meta name="citation_author_institution" content="Amgen Discovery Research, Thousand Oaks, California" /><meta name="citation_author" content="Kelly Hanestad" /><meta name="citation_author_institution" content="Amgen Discovery Research, Thousand Oaks, California" /><meta name="citation_author" content="John D. Crispino" /><meta name="citation_author_institution" content="Division of Hematology/Oncology, Northwestern University, Chicago, Illinois." /><meta name="citation_author" content="Gloria Juan" /><meta name="citation_author_institution" content="Amgen Medical Sciences, Thousand Oaks, California" /><meta name="citation_author" content="Angela Coxon" /><meta name="citation_author_institution" content="Amgen Discovery Research, Thousand Oaks, California" /><meta name="citation_publication_date" content="2018/12" /><meta name="citation_issue" content="12" /><meta name="citation_volume" content="17" /><meta name="citation_firstpage" content="2575" /><meta name="citation_doi" content="10.1158/1535-7163.MCT-18-0186" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC6279493/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC6279493/" /><meta name="citation_pmid" content="30266802" /><meta name="DC.Title" content="Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="NIH Public Access" /><meta name="DC.Contributor" content="Marc Payton" /><meta name="DC.Contributor" content="Hung-Kam Cheung" /><meta name="DC.Contributor" content="Maria Stefania S. Ninniri" /><meta name="DC.Contributor" content="Christian Marinaccio" /><meta name="DC.Contributor" content="William C. Wayne" /><meta name="DC.Contributor" content="Kelly Hanestad" /><meta name="DC.Contributor" content="John D. Crispino" /><meta name="DC.Contributor" content="Gloria Juan" /><meta name="DC.Contributor" content="Angela Coxon" /><meta name="DC.Date" content="2018 Dec" /><meta name="DC.Identifier" content="10.1158/1535-7163.MCT-18-0186" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes" /><meta property="og:type" content="article" /><meta property="og:description" content="Aurora kinase A and B have essential and non-overlapping roles in mitosis, with elevated expression in a subset of human cancers, including acute myeloid leukemia (AML). In this study, pan-aurora kinase inhibitor (AKI) AMG 900 distinguishes itself as ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279493/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means itâ€™s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure youâ€™re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6279493/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC6279493
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC6279493/pdf/nihms-1508729.pdf" class="int-view">PDF (1.7M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/6279493/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/6279493/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="6279493" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6279493%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="CBM7JBHrDuaa8yCEh6EG67CGExuQqBhA0Ek0E3cjA79Fc6IN2aZQWGSgmJXs5tH6">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6279493%2F&amp;text=Dual%20targeting%20of%20aurora%20kinases%20with%20AMG%20900%20exhibits%20potent%20preclinical%20activity%20against%20acute%20myeloid%20leukemia%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6279493%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279493/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC6279493/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/30266802/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC6279493/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/30266802/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC6279493/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/6279493/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC6279493
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-nihpa.png" alt="Logo of nihpa" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://www.hhs.gov/open/public-access-guiding-principles/index.html" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div><span id="pmcmata">Mol Cancer Ther.</span> Author manuscript; available in PMC 2019 Dec 1.</div><div></div><div class="final-form"><em>Published in final edited form as:</em></div><div class="final-citation"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=30266802" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Mol Cancer Ther. 2018 Dec; 17(12): 2575â€“2585. </a></div><span class="fm-vol-iss-date">Published online 2018 Sep 28. </span> <span class="doi"><span>doi:Â </span><a href="//doi.org/10.1158%2F1535-7163.MCT-18-0186" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1158/1535-7163.MCT-18-0186</a></span></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC6279493</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS1508729</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30266802">30266802</a></div></div></div><h1 class="content-title">Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Payton%20M%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653343985296" co-class="co-affbox">Marc Payton</a>,<sup>1,</sup><sup>^</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20HK%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653342928960" co-class="co-affbox">Hung-Kam Cheung</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ninniri%20MS%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653342926976" co-class="co-affbox">Maria Stefania S. Ninniri</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Marinaccio%20C%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653339569584" co-class="co-affbox">Christian Marinaccio</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wayne%20WC%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653339567600" co-class="co-affbox">William C. Wayne</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hanestad%20K%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653336140608" co-class="co-affbox">Kelly Hanestad</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Crispino%20JD%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653336138624" co-class="co-affbox">John D. Crispino</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Juan%20G%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653336136640" co-class="co-affbox">Gloria Juan</a>,<sup>2</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Coxon%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm140653335732544" co-class="co-affbox">Angela Coxon</a><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140653343985296"><h3 class="no_margin">Marc Payton</h3><p><sup>1</sup>Amgen Discovery Research, Thousand Oaks, California</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Payton%20M%5BAuthor%5D">Marc Payton</a></div></div><div id="_co_idm140653342928960"><h3 class="no_margin">Hung-Kam Cheung</h3><p><sup>2</sup>Amgen Medical Sciences, Thousand Oaks, California</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20HK%5BAuthor%5D">Hung-Kam Cheung</a></div></div><div id="_co_idm140653342926976"><h3 class="no_margin">Maria Stefania S. Ninniri</h3><p><sup>1</sup>Amgen Discovery Research, Thousand Oaks, California</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ninniri%20MS%5BAuthor%5D">Maria Stefania S. Ninniri</a></div></div><div id="_co_idm140653339569584"><h3 class="no_margin">Christian Marinaccio</h3><p><sup>3</sup>Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Marinaccio%20C%5BAuthor%5D">Christian Marinaccio</a></div></div><div id="_co_idm140653339567600"><h3 class="no_margin">William C. Wayne</h3><p><sup>1</sup>Amgen Discovery Research, Thousand Oaks, California</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wayne%20WC%5BAuthor%5D">William C. Wayne</a></div></div><div id="_co_idm140653336140608"><h3 class="no_margin">Kelly Hanestad</h3><p><sup>1</sup>Amgen Discovery Research, Thousand Oaks, California</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hanestad%20K%5BAuthor%5D">Kelly Hanestad</a></div></div><div id="_co_idm140653336138624"><h3 class="no_margin">John D. Crispino</h3><p><sup>3</sup>Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Crispino%20JD%5BAuthor%5D">John D. Crispino</a></div></div><div id="_co_idm140653336136640"><h3 class="no_margin">Gloria Juan</h3><p><sup>2</sup>Amgen Medical Sciences, Thousand Oaks, California</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Juan%20G%5BAuthor%5D">Gloria Juan</a></div></div><div id="_co_idm140653335732544"><h3 class="no_margin">Angela Coxon</h3><p><sup>1</sup>Amgen Discovery Research, Thousand Oaks, California</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Coxon%20A%5BAuthor%5D">Angela Coxon</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140653346000432_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140653346000432_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140653346000432_ai" style="display:none"><div class="fm-affl" id="A1"><sup>1</sup>Amgen Discovery Research, Thousand Oaks, California</div><div class="fm-affl" id="A2"><sup>2</sup>Amgen Medical Sciences, Thousand Oaks, California</div><div class="fm-affl" id="A3"><sup>3</sup>Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.</div><div id="CR1"><sup>^</sup>Corresponding Author: Marc N. Payton, Discovery Research, Amgen Inc., One Amgen Center Thousand Oaks CA 91320. Phone: (805) 447-6697; <a href="mailto:dev@null" data-email="moc.negma@notyapm" class="oemail">moc.negma@notyapm</a></div></div><div class="fm-article-notes half_rhythm"></div><div class="permissions half_rhythm hide" id="idm140653346000432_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">PMC Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm" role="complementary" aria-label="Related or updated information about this article."><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=30266802" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Mol Cancer Ther</a></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>1.</strong></div><div><a href="/pmc/articles/PMC6279493/bin/NIHMS1508729-supplement-1.docx" data-ga-action="click_feat_suppl">NIHMS1508729-supplement-1.docx</a><span style="color:gray"> (2.8M)</span></div><div class="small guid">GUID:Â B87DA8C3-FB9B-4153-B62A-C9E9641D0B34</div></div></dd></dl></div><div id="ABS1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="ABS1title">Abstract</h2><!--article-meta--><div><p id="P1" class="p p-first-last">Aurora kinase A and B have essential and non-overlapping roles in mitosis, with elevated expression in a subset of human cancers, including acute myeloid leukemia (AML). In this study, pan-aurora kinase inhibitor (AKI) AMG 900 distinguishes itself as an anti-leukemic agent that is more uniformly potent against a panel of AML cell lines than are isoform-selective AKIs and classic AML drugs. AMG 900 inhibited AML cell growth by inducing polyploidization and/or apoptosis. AMG 900 and aurora-B selective inhibitor AZD1152-hQPA showed comparable cellular effects on AML lines that do not harbor a <em>FLT3</em>-ITD mutation. AMG 900 was active against P-glycoprotein-expressing AML cells resistant to AZD1152-hQPA and was effective at inducing expression of megakaryocyte-lineage markers (CD41, CD42) on human CHRF-288&#x02013;11 cells and mouse <em>Jak2</em><sup>V617F</sup> cells. In MOLM-13 cells, inhibition of p-histone H3 by AMG 900 was associated with polyploidy, extra centrosomes, accumulation of p53 protein, apoptosis, and cleavage of Bcl-2 protein. Co-administration of cytarabine (Ara-C) with AMG 900 potentiated cell killing in a subset of AML lines, with evidence of attenuated polyploidization. AMG 900 inhibited the proliferation of primary human bone marrow cells in culture, with a better proliferation recovery profile relative to classic anti-mitotic drug docetaxel. <em>In vivo</em>, AMG 900 significantly reduced tumor burden in a systemic MOLM-13 xenograft model where we demonstrate the utility of 3&#x02019;-deoxy-3&#x02019;&#x02212;<sup>18</sup>F-fluorothymidine [<sup>18</sup>F]FLT positron emission tomographic (PET)&#x02013;computed tomographic (CT) imaging to measure the anti-proliferative effects of AMG 900 in skeletal tissues in mice.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">AMG 900, AML, aurora kinase, mitosis</span></div></div><div id="S1" class="tsec sec"><h2 class="head no_bottom_margin" id="S1title">Introduction</h2><p id="P2" class="p p-first">AML is a genetically heterogeneous disease that accounts for approximately 33% of newly diagnosed adult leukemia (<a href="#R1" rid="R1" class=" bibr popnode">1</a>). In AML, defects in myeloid-lineage differentiation leads to clonal expansion of precursor cells that is fueled by pro-proliferative and pro-survival pathway signaling. Standard-of-care therapy for most younger adult AML patients is high-dose induction chemotherapy (daunorubicin and Ara-C) followed by post-remission treatments that include additional chemotherapy (consolidation) as well as allogeneic stem cell transplantation (<a href="#R2" rid="R2" class=" bibr popnode">2</a>). Recently, the first multi-targeted kinase inhibitor (midostaurin) was approved in combination with chemotherapy for treating newly diagnosed AML patients with <em>FLT3</em> mutations (<a href="#R3" rid="R3" class=" bibr popnode">3</a>). Elderly AML patients are often unfit for the intensive chemotherapy and therefore rely on less effective therapies such as low-dose Ara-C (LDAC). Furthermore, the disease in elderly AML patients may have unfavorable characteristics (<em>TP53</em> mutations, chromosome 5q and 7q deletions, P-glycoprotein (P-gp) expression) that have limited benefit from current therapies (<a href="#R4" rid="R4" class=" bibr popnode">4</a>).</p><p id="P3">Aurora kinases (AK) A and B are essential mitotic regulators having both distinct functions and subcellular localization (<a href="#R5" rid="R5" class=" bibr popnode">5</a>). The expression of aurora-A and -B is elevated in a variety of human cancers, including AML (<a href="#R6" rid="R6" class=" bibr popnode">6</a>&#x02013;<a href="#R8" rid="R8" class=" bibr popnode">8</a>). The spindle assembly checkpoint (SAC) is a surveillance mechanism that governs mitotic progression by ensuring proper microtubule-attachment to sister chromatids at the kinetochore to achieve bipolar orientation and tension at metaphase. A classic hallmark of mitosis is the phosphorylation of histone H3 on serine-10 (p-histone H3) by aurora-B. Selective aurora-A inhibition leads to an increase in p-histone H3 and SAC activation which delays mitotic progression, whereas selective aurora-B or dual AK inhibition leads to a decrease in p-histone H3 and SAC silencing resulting in exit from mitosis without division (<a href="#R5" rid="R5" class=" bibr popnode">5</a>).</p><p id="P4">MLN8054 and MLN8237 (alisertib) are isoform-selective inhibitors of aurora-A (<a href="#R9" rid="R9" class=" bibr popnode">9</a>, <a href="#R10" rid="R10" class=" bibr popnode">10</a>), whereas AZD1152-hQPA (barasertib) targets aurora-B and FLT3 kinase activity with a 1000-fold selectivity over aurora-A (<a href="#R11" rid="R11" class=" bibr popnode">11</a>, <a href="#R12" rid="R12" class=" bibr popnode">12</a>). In clinical studies, alisertib and barasertib have shown single-agent anti-leukemia activity in AML [overall response rate of 17% (pretreated, <a id="__tag_738135340" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00830518" ref="reftype=extlink-clinical-trial&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00830518","term_id":"NCT00830518"}}</span>NCT00830518</a>) and 35% (older newly diagnosis, <a id="__tag_738135336" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00952588" ref="reftype=extlink-clinical-trial&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00952588","term_id":"NCT00952588"}}</span>NCT00952588</a>), respectively] with on-target toxicities observed in proliferating normal tissues (<a href="#R13" rid="R13" class=" bibr popnode">13</a>&#x02013;<a href="#R15" rid="R15" class=" bibr popnode">15</a>). Recent studies have shown that MLN8237 induces differentiation of acute megakaryoblastic leukemia (AMKL) cells, with potent anti-leukemia activity (<a href="#R16" rid="R16" class=" bibr popnode">16</a>&#x02013;<a href="#R18" rid="R18" class=" bibr popnode">18</a>); these findings have led to a clinical study specifically targeting AMKL and primary myelofibrosis (PMF) (<a id="__tag_738135339" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02530619" ref="reftype=extlink-clinical-trial&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02530619","term_id":"NCT02530619"}}</span>NCT02530619</a>). Factors limiting the efficacy of AKIs may include quiescence (arrested state), such as in leukemic stem cells (<a href="#R19" rid="R19" class=" bibr popnode">19</a>, <a href="#R20" rid="R20" class=" bibr popnode">20</a>); expression of drug-efflux transporters such as P-gp and BCRP1 (<a href="#R21" rid="R21" class=" bibr popnode">21</a>, <a href="#R22" rid="R22" class=" bibr popnode">22</a>); and acquisition of target-modifying mutations in <em>AURKA</em> or <em>AURKB</em> (<a href="#R23" rid="R23" class=" bibr popnode">23</a>, <a href="#R24" rid="R24" class=" bibr popnode">24</a>). To our knowledge, an inhibitor that is equipotent against aurora-A and -B and highly selective against other kinases has not been evaluated against isoform-selective AKIs in a panel of AML cell lines.</p><p id="P5">AMG 900 is a potent and highly selective pan-AKI with activity across solid tumor cell lines <em>in vitro,</em> and is effective at inhibiting the growth of taxane-resistant tumor xenografts <em>in vivo</em> (<a href="#R24" rid="R24" class=" bibr popnode">24</a>&#x02013;<a href="#R26" rid="R26" class=" bibr popnode">26</a>). A recent study demonstrated that AMG 900 is more lethal to breast cancer cells with p53 pathway dysfunction (<a href="#R27" rid="R27" class=" bibr popnode">27</a>). In combination studies, AMG 900 can potentiate the activity of histone deacetylase inhibitors and microtubule-targeting agents in preclinical tumor models (<a href="#R26" rid="R26" class=" bibr popnode">26</a>, <a href="#R28" rid="R28" class=" bibr popnode">28</a>). In a phase-1 dose escalation study in AML patients (relapsed/refractory, <a id="__tag_738135338" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01380756" ref="reftype=extlink-clinical-trial&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01380756","term_id":"NCT01380756"}}</span>NCT01380756</a>), AMG 900 had a response rate of 9% (3-of-35 achieved a complete response with an incomplete count recovery), with cases of prolonged cytopenia, a prototypical AKI class effect (<a href="#R29" rid="R29" class=" bibr popnode">29</a>).</p><p id="P6" class="p p-last">In this report, we describe the effects of AMG 900, isoform-selective AKIs, and two classic anti-AML drugs on a diverse panel of AML cell lines. We assess the activity of AMG 900 on P-gp expressing AML cells, and its effects on expression of megakaryocyte-lineage markers as well as p53 and intrinsic apoptosis signaling pathways. We combine LDAC with AMG 900 in a subset of AML lines and perform expanded single-agent drug action studies using MOLM-13 cells and human bone marrow mononuclear cells (HBMNC) in culture. We investigate the anti-leukemia effects of AMG 900 using a systemic MOLM-13 xenograft model and evaluate the anti-proliferative response using PET/CT imaging to measure the level of [<sup>18</sup>F]FLT in skeletal tissue in mice.</p></div><div id="S2" class="tsec sec"><h2 class="head no_bottom_margin" id="S2title">Materials and Methods</h2><div id="S3" class="sec sec-first"><h3 id="S3title">Small molecules.</h3><p id="P7" class="p p-first-last">AKIs include AMG 900 (in-house synthesis), MLN8054/MLN8237 (Selleck Chemicals), and AZD1152-hQPA (in-house synthesis); molecular structures have previously been reported (<a href="#R25" rid="R25" class=" bibr popnode">25</a>). Test compounds include Ara-C (Sigma), daunorubicin (Sigma), docetaxel (Sanofi-Aventis), nocodazole (Sigma), nutlin-3a (Sigma), and GF120918 (Sigma) (<a href="#R30" rid="R30" class=" bibr popnode">30</a>).</p></div><div id="S4" class="sec"><h3 id="S4title">Cells and culture conditions.</h3><p id="P8" class="p p-first-last">Human AML cell lines were procured from ATCC or DSMZ and authenticated by ATCC using short tandem repeat DNA analysis. MOLM-13-Luc cell line expressing luciferase was established at Amgen Inc. (<a href="#R31" rid="R31" class=" bibr popnode">31</a>). MOLM-13-Luc cells were negative for mycoplasma by DNA analysis (Charles River), the remaining AML cell lines have not been recently retested for the presence of mycoplasma. Cell lines were grown using recommended culture conditions and maintained at 37&#x000b0;C with 5% CO<sub>2</sub>, a subset of lines were grown in the presence of penicillin/streptomycin (Invitrogen). Primary human bone marrow mononuclear cells (LONZA) were grown in 15% FBS in IMDM media supplemented with 2.5 ng/mL G-CSF, 2.5 ng/mL GM-CSF, and 10 ng/mL SCF (R&#x00026;D Systems). To differentiate primary mouse bone marrow cell cultures to megakaryocytic lineage, c-kit+ progenitor cells were positively enriched from whole bone marrow obtained from <em>Jak2</em><sup>V617F</sup> knock-in mice using MACS system (Miltenyi Biotech). Enriched c-kit+ progenitor cells were grown in StemSpan Media (Stemcell Technologies) supplemented with 10 ng/mL mouse IL-3, 10 ng/mL human IL-6, 40 ng/mL mouse SCF, and 20 &#x003bc;g/mL human low-density lipoprotein (Stemcell Technologies) for 24 hours. Megakaryocytic differentiation was performed by culturing cells in 10% FBS in RPMI1640 media supplemented with 50 ng/mL mouse thrombopoietin (Stemcell Technologies).</p></div><div id="S5" class="sec"><h3 id="S5title">Animals.</h3><p id="P9" class="p p-first-last">All experimental procedures were conducted in accordance with the Institutional Animal Care and Use Committee Protocol at Molecular Imaging Inc. (Ann Arbor, Michigan), the U.S. Department of Agriculture regulations, and met all the Association for Assessment and Accreditation of Laboratory Animal Care specifications. NOD/SCID IL-2R&#x003b3;&#x02212;/&#x02212; (NSG) mice (Jackson Laboratory) were housed in sterilized cages maintained under aseptic and pathogen-free conditions. Food, water, and nutritional supplements were offered on a daily basis during the study. AMG 900 was formulated as a suspension in 2% HPMC, 1% Tween-80, at pH 2.2 and administered based on individual body weight.</p></div><div id="S6" class="sec"><h3 id="S6title">Western blot analysis.</h3><p id="P10" class="p p-first-last">Whole cell lysates were prepared using RIPA Buffer (Sigma) supplemented with protease and phosphatase inhibitor cocktail (Roche). Primary antibodies [cl-caspase-3 (04&#x02013;439), Bcl-2 (05&#x02013;729), Bax (MAB4601) Millipore; p53 (9282), Mcl-1 (5453), GAPDH (14C10) CST; p21 (sc-6246) SCBT; MDM2 (MA1&#x02013;113) Invitrogen; Bcl-xL (ab98143) Abcam; aurora-A (610938), aurora-B (611082) BD Biosciences; &#x003b2;-actin (A5441) Sigma]. Secondary detection performed using anti-rabbit or anti-mouse IgG Vectastain ABC kit (Vector Laboratories) and detected with Lightning-ECL kit (PerkinElmer).</p></div><div id="S7" class="sec"><h3 id="S7title">Confocal imaging.</h3><p id="P11" class="p p-first-last">MOLM-13 cells were treated with AMG 900 at 10 nmol/L or DMSO for 48 hours. Formaldehyde (4%) fixed cells were stained with anti-p-histone H3 (05&#x02013;806, Millipore) and anti-pericentrin antibodies (ab4448, Abcam). Secondary detection was performed using anti-mouse-alexa555 (A21422) and anti-rabbit-alexa488 (A11008) antibodies from Invitrogen and DNA was stained with 4&#x02019;,6-diamidino-2-phenylindole (DAPI, CalBiochem). Stained cells were spotted on glass slides, treated with antifade reagent (Invitrogen), and mounted with coverslips in preparation for confocal imaging using Nikon Eclipse TE2000 inverted microscope (60x objective) running Nikon Elements software.</p></div><div id="S8" class="sec sec-last"><h3 id="S8title"><em>In vivo</em> imaging.</h3><p id="P12" class="p p-first">NSG female mice were injected intravenous (IV) with 5&#x000d7;10<sup>4</sup> human MOLM-13-Luc luciferase cells. Xenogen IVIS bioluminescence (BLI) imaging platform (PerkinElmer) was used to acquire whole body BLI for each animal to confirm tumor establishment. Mice were injected intraperitoneal (IP) with 150 mg/kg of luciferin based on body weight and imaged 10 to15 minutes later as per manufactures instructions. Whole body [<sup>18</sup>F]FLT-PET/CT imaging was conducted using sequential Siemens Focus micro-PET (200uCi [<sup>18</sup>F]FLT IV, 60 minute incubation time, followed by 10 minute static scan) and Gamma Medica FLEX micro-CT (80 kVp, 440 uA). Nine days after tumor injection, mice with tumor burden were randomized into three treatment groups (n = 10 per group): vehicle alone (7 days daily, oral (PO)), AMG 900 at 22 mg/kg (4 days daily, PO), and AMG 900 at 12.6 mg/kg (7 days daily, PO). [<sup>18</sup>F]FLT measurements were recorded at baseline (one day before treatment) and on days 5, 8, 11, and 14 post-treatment start. BLI measurements were collected on day 1 (before dosing on the day of treatment initiation) and on days 6, 9, 12, 15 post-treatment start. Data is represented as mean whole body BLI signal (photons/second, as per Xenogen instructions) or mean skeleton [<sup>18</sup>F]FLT signal &#x000b1; SEM. To quantify skeleton [<sup>18</sup>F]FLT signal, a custom analysis program created by inviCRO Inc. (Boston, MA) was used to capture the whole body skeletal bone volume based on CT segmentation algorithm. CT derived skeleton regions-of-interest were used to quantitate the percentage of injected [<sup>18</sup>F]FLT dose per gram of tissue (%ID/g). Statistical significance for [<sup>18</sup>F]FLT and BLI was determined by comparing treated groups versus vehicle-control group using paired t-test. Study and image analysis was performed by inviCRO Inc..</p><p id="P13" class="p p-last">Details about high-content cell imaging and flow cytometry (FC) assays are described in the <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Materials and Methods</a>.</p></div></div><div id="S9" class="tsec sec"><h2 class="head no_bottom_margin" id="S9title">Results</h2><div id="S10" class="sec sec-first"><h3 id="S10title">AMG 900 blocks proliferation of AML cell lines through polyploidization and apoptosis, with a distinct sensitivity profile relative to isoform-selective AKIs.</h3><p id="P14" class="p p-first">We first investigated the anti-proliferative effects of three AKIs [AMG 900 (pan), AZD1152-hQPA (B-selective), and MLN8054 (A-selective)] as well as Ara-C and daunorubicin in a panel of AML cell lines. Cells were treated with each test agent for 72 hours and processed for FC to measure absolute cell count, cell death (apoptosis and subG<sub>1</sub>), and polyploidy (&#x02265; 4N DNA content) (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S1A and B</a>). As shown in <a href="/pmc/articles/PMC6279493/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>, AMG 900 inhibited the growth of AML lines at low nanomolar concentrations, with largely uniform potency relative to the other test agents. The level of polyploidization and cell death induced by AMG 900 varied across AML lines, with three principal phenotypes observed polyploidy or cell death alone, and most frequently polyploidy with cell death (<a href="/pmc/articles/PMC6279493/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1B</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S1C and D</a>). The FLT3-ITD-expressing MOLM-13 and MV-411 cells showed a bell-shaped polyploidy profile with AZD1152-hQPA, in contrast to a stable polyploidy profile with AMG 900, consistent with a recent study identifying FLT3-ITD in AML as a target of AZD1152-hQPA (<a href="#R12" rid="R12" class=" bibr popnode">12</a>). The cell-cycle effects observed with Ara-C (S-phase) and daunorubicin (G<sub>2</sub>M) were distinct from AKI mode-of-action (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S1E</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC6279493/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140653337720000"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6279493_nihms-1508729-f0001.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1508729-f0001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6279493/bin/nihms-1508729-f0001.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140653337720000"><a target="object" rel="noopener" href="/pmc/articles/PMC6279493/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC6279493/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1.</a></div><!--caption a7--><div class="caption"><p id="P32">AMG 900 exhibits potent anti-leukemia activity on AML cell lines with a distinct sensitivity profile relative to isoform-selective AKIs. <strong>A</strong> and <strong>B,</strong> AML cell lines were treated with DMSO or test agents at eleven concentrations [three-point dilution, high concentration AMG 900 (0.1 &#x003bc;mol/L), MLN8054 and AZD1152-hQPA (5 &#x003bc;mol/L), Ara-C and daunorubicin (20 &#x003bc;mol/L)] for 72 hours. Cell count and apoptosis/DNA content analysis. <strong>A,</strong> Cell count potency determined for individual AML lines (n = 11), with mean and median EC<sub>50</sub> values noted below. *OCI-AML-3 data not included in graph for Ara-C (EC<sub>50</sub> &#x0003e; 1 &#x003bc;mol/L). <strong>B,</strong> AKI dose-response profiles for MOLM-13, KG-1a, and HL-60 cells showing percentage of &#x02265; 4N DNA content and total cell death (subG<sub>1</sub> + cl-caspase-3) populations (mean &#x000b1; SD). <strong>C,</strong> MOLM-13, KG-1, HEL, and MEGAL cells treated with AMG 900, MLN8054, and AZD1152-hQPA or DMSO for 48 hours. Heatmaps showing p-histone H3 positivity represented as a mean percentage of control (POC). SAC activation (p-histone H3 POC &#x0003e; 100, <em>white</em> to <em>red</em>) and SAC silencing (p-histone H3 POC &#x0003c; 100, <em>white</em> to <em>blue</em>). <strong>D,</strong> Histogram of MOLM-13, KG-1, HEL cells stained with P-gp (<em>blue</em>) and isotype (<em>red</em>) antibodies, and unstained control (<em>black</em>). MES-SA/Dx5 cells were included as P-gp control. <strong>E,</strong> DNA content analysis of HEL cells treated with AMG 900 or AZD1152-hQPA &#x000b1; P-gp inhibitor GF120918. Dose-response of AKI alone (<em>blue</em>) and in combination with P-gp inhibitor (<em>red</em>).</p></div></div></div><p id="P15" class="p p-last">Next, we determined the AKI effective concentration for either SAC activation or silencing by monitoring p-histone H3 levels. As shown in <a href="/pmc/articles/PMC6279493/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1C</span></a>, inhibition of aurora-B activity by AMG 900 or AZD1152-hQPA led to p-histone H3 decrease and SAC silencing. In agreement with cell count data (in <a href="/pmc/articles/PMC6279493/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1A</span></a>), the two erythroleukemic lines (HEL and KG-1) were much less sensitive to AZD1152-hQPA than MOLM-13 and MEGAL cells were. MLN8054 markedly increased p-histone H3 except in MOLM-13 cells where the magnitude of SAC activation was notably lower. We observed a significantly lower level of aurora-A protein accumulation after nocodazole treatment in MOLM-13 cells than in KG-1, HEL, and MEGAL cells, suggesting the lower level of p-histone H3 accumulation after MLN8054 treatment may be due to a weakened SAC response in MOLM-13 cells (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S2</a>). At higher concentrations of MLN8054 (&#x02265; 2 &#x003bc;mol/L), we observed SAC silencing in three of four cell lines suggesting the compound can act as a pan-AKI. To confirm the mechanism of resistance to AZD1152-hQPA, we determined that HEL and KG-1 cells overexpress P-gp, and showed that co-administration of P-gp/BCRP1 inhibitor GF120918 (<a href="#R30" rid="R30" class=" bibr popnode">30</a>, <a href="#R32" rid="R32" class=" bibr popnode">32</a>) re-sensitized HEL cells to AZD1152-hQPA relative to AMG 900 (<a href="/pmc/articles/PMC6279493/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1D and E</span></a>). Collectively, these data show that AMG 900 is more uniformly potent across AML lines with some overlapping and distinct features relative to isoform-selective AKIs.</p></div><div id="S11" class="sec"><h3 id="S11title">AMG 900 induces polyploidization and differentiation of lineage-committed malignant megakaryocytes.</h3><p id="P16" class="p p-first-last">During normal maturation, megakaryocyte precursor cells become polyploid through a process termed endomitosis, where repeated rounds of DNA replication lead to large cells that permanently exit the cell cycle with nuclei containing 16N to 64N DNA content. Polyploidy inducers can fuel terminal differentiation of AMKL cells, producing similar cellular effects to those that occur during megakaryocyte maturation (<a href="#R18" rid="R18" class=" bibr popnode">18</a>). To investigate the effects of pan-AK inhibition as a potential driver of cell differentiation, CHRF-288&#x02013;11 AMKL cells were treated with AMG 900 or MLN8237. As shown in <a href="/pmc/articles/PMC6279493/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2A and B</span></a>, both AKIs induced similar megakaryocyte maturation features as evidenced by the cell size, nuclear/cytoplasmic morphologies, level of polyploidization, and co-expression of CD41/CD42. Previous studies with MLN8237 demonstrated that inhibition of aurora-A promoted these same hallmarks of megakaryocyte maturation in HEL and SET-2 AML cell lines as well as in mouse bone marrow cells harboring <em>Jak2</em><sup>V617F</sup> knock-in mutation (<a href="#R16" rid="R16" class=" bibr popnode">16</a>, <a href="#R17" rid="R17" class=" bibr popnode">17</a>). With this in mind, we investigated whether pan-AK inhibition would affect differentiation of <em>Jak2</em><sup>V617F</sup>-expressing mouse bone marrow cell cultures. As shown in <a href="/pmc/articles/PMC6279493/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2C and D</span></a>, treatment with AMG 900 significantly increased polyploidization and expression of CD41/CD42 in a subset of mouse cells, where the level of differentiation was less for MLN8237 and failed to reach statistical significance.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC6279493/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140653340078288"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6279493_nihms-1508729-f0002.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1508729-f0002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6279493/bin/nihms-1508729-f0002.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140653340078288"><a target="object" rel="noopener" href="/pmc/articles/PMC6279493/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC6279493/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2.</a></div><!--caption a7--><div class="caption"><p id="P33">AMG 900 induces polyploidization and the expression of megakaryocyte-lineage differentiation markers. CHRF-288&#x02013;11 AMKL cells and <em>Jak2</em><sup>V617F</sup> knock-in mouse bone marrow cells were treated with MLN8237 and AMG 900 at 0.3 &#x003bc;mol/L or DMSO for 72 hours. <strong>A</strong> and <strong>C,</strong> Representative images of Wright-Giemsa stained cells (magnification x400), CD41/CD42 expression, and DNA content profiles. <strong>B</strong> and <strong>D,</strong> Percentage of CD41<sup>+</sup>/CD42<sup>+</sup> and &#x0003e; 4N DNA content gated CHRF-288&#x02013;11 and <em>Jak2</em><sup>V617F</sup> gated populations (mean &#x000b1; SD). CHRF-288&#x02013;11 cells [MLN8237 and AMG 900 versus DMSO (CD41<sup>+</sup>/CD42<sup>+</sup> and DNA ploidy, *<em>P</em> &#x02264; 0.0009)]. <em>Jak2</em><sup>V617F</sup> cells from five individual mice [MLN8237 versus DMSO (CD41<sup>+</sup>/CD42<sup>+</sup>
<em>P</em> = 0.1993, DNA ploidy <em>P</em> = 0.5334, not significant (ns); AMG 900 versus DMSO (CD41<sup>+</sup>/CD42<sup>+</sup> and DNA ploidy *<em>P</em> &#x02264; 0.0007)].</p></div></div></div></div><div id="S12" class="sec"><h3 id="S12title">AMG 900 induces apoptosis independent of p53 post-mitotic G1 checkpoint activation.</h3><p id="P17" class="p p-first-last">To examine the effects of pan-AK inhibition on p53 signaling we treated <em>TP53</em>
<sup>WT</sup> (GDM-1, MOLM-13) and <em>TP53</em><sup>MUT</sup> (U937, HEL) AML lines with AMG 900 for 48 hours. As shown in <a href="/pmc/articles/PMC6279493/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3A</span></a>, AMG 900 markedly increased cl-caspase-3 protein levels in GDM-1, MOLM-13, and U937 cells, whereas HEL cells largely evaded apoptosis. Total p53 protein levels increased after AMG 900 treatment in both <em>TP53</em>
<sup>WT</sup> lines, which coincided with an increase in p21 protein levels in GDM-1 cells, but not in MOLM-13 cells. Surprised by these findings, we evaluated the p53 and p21 induction profile over a wider concentration range of AMG 900 in MOLM-13 cells and found a low level of p21 protein induction only near the inflection point (1.2 nmol/L), whereas p53 and cl-caspase-3 protein levels, and polyploidy increased in a parallel manner (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S3</a>). In contrast to the other three AML lines, GDM-1 cells treated with AMG 900 showed a prominent 4N DNA content peak, consistent with attenuation of polyploidization mediated by p21-induced growth arrest (<a href="/pmc/articles/PMC6279493/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3B</span></a>) (<a href="#R33" rid="R33" class=" bibr popnode">33</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC6279493/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140653341995296"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6279493_nihms-1508729-f0003.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1508729-f0003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6279493/bin/nihms-1508729-f0003.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140653341995296"><a target="object" rel="noopener" href="/pmc/articles/PMC6279493/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC6279493/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3.</a></div><!--caption a7--><div class="caption"><p id="P34">AMG 900 can increase polyploidy, apoptosis, and p53 protein levels in AML cell lines, and can potentiate the activity of LDAC. <strong>A</strong> and <strong>B,</strong> U937 (<em>TP53</em><sup>MUT</sup>), HEL (<em>TP53</em><sup>MUT</sup>), GDM-1 (<em>TP53</em><sup>WT</sup>), and MOLM-13 (<em>TP53</em><sup>WT</sup>) cells were treated with AMG 900 at 33 nmol/L or DMSO for 48 hours. Western blot and cell-cycle analysis. <strong>A,</strong> Protein expression profiles of cl-caspase-3, total p53, p21, and &#x003b2;-actin. <strong>B,</strong> DNA content profiles with indicated Y-axis maximal (Y-max) count and ploidy (2N to 16N). <strong>C</strong> and <strong>D,</strong> AML cells treated with AMG 900, Ara-C, or DMSO, and in combination using 4 &#x000d7; 3 dose-matrix for 72 hours. Annexin-V apoptosis analysis. <strong>C,</strong> Representative scatter plots of annexin-V positivity percentages (<em>red</em>) for test agent alone and combined AMG 900 (4.0 nmol/L) and Ara-C (125 nmol/L). <strong>D,</strong> Percentage of annexin-V positivity across dose-matrix. <strong>E</strong> and <strong>F,</strong> MOLM-13 cells were treated with test agent alone at the indicated concentrations and in combination for 72 hours. Apoptosis and cell-cycle analysis. <strong>E,</strong> DNA content profiles with cl-caspase-3 positive population (<em>red</em>) with Y-max count and ploidy (2N to 16N). <strong>F,</strong> Percentage of total cell death (subG<sub>1</sub> + cl-capase-3) and &#x02265; 4N DNA content (mean &#x000b1; SD).</p></div></div></div></div><div id="S13" class="sec"><h3 id="S13title">AMG 900 can potentiate cell killing in combination with LDAC.</h3><p id="P18" class="p p-first-last">To determine the effectiveness of AMG 900 in combination with LDAC, we designed a dose-matrix (1 to 4 nmol/L by 31 to 125 nmol/L, respectively) using U937, HEL, GDM-1, and MOLM-13 cells. After 72 hours, we determined the fraction of cells positive for apoptosis using annexin-V FC assay (<a href="/pmc/articles/PMC6279493/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3C and D</span></a>). The level of cell killing induced by combined AMG 900 and Ara-C varied, MOLM-13 and HEL showed a net increase in apoptosis relative to that induced by AMG 900 alone, whereas the combination was less effective than AMG 900 alone against U937 and GDM-1 cells. Based on the positive drug interaction on MOLM-13 cells, we next examined the cell cycle effects of combining AMG 900 and Ara-C. As shown in <a href="/pmc/articles/PMC6279493/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3E and F</span></a>, we observed an increase in subG<sub>1</sub> and cl-caspase-3 gated populations (represented as total death) with a dose-dependent attenuation of polyploidization, suggesting the agents can act together to induce an effect not observed with either agent alone (neomorphic effect). Median dose-effect analysis using the Chou-Talalay method (<a href="#R34" rid="R34" class=" bibr popnode">34</a>) showed that MOLM-13 cells treated with AMG 900 plus Ara-C combination in a cell growth assay had additive to weak synergy (combination index score of 1 to 0.7, respectively) (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S4</a>).</p></div><div id="S14" class="sec"><h3 id="S14title">Inhibition of aurora kinase activity in MOLM-13 cells by AMG 900 leads to accumulation of centrosomes, induction of the intrinsic apoptotic pathway, and cleavage of Bcl-2.</h3><p id="P19" class="p p-first-last">To understand the phenotypes and signaling events triggered by AMG 900, we selected MOLM-13 cells as a representative AML line for further studies. As shown in <a href="/pmc/articles/PMC6279493/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4A</span></a>, DMSO-treated mitotic cells exhibited strong p-histone H3 immunoreactivity with condensed sister chromatids, and two centrosome centers. In contrast, AMG 900-treated mitotic cells showed a significant decrease in p-histone H3 associated with an accumulation of centrosomes and DNA content. Interestingly, a low-level of p-histone H3 signal was detectable in a subset of AMG 900 treated mitotic cells that had supernumerary centrosomes (eight pericentrin spots) and higher ploidy content (<a href="/pmc/articles/PMC6279493/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4A</span></a>, lower panel). One explanation for the residual p-histone H3 staining may be amplification of aurora-B gene dosage resulting from polyploidization. We next examined the effects of AMG 900 on intrinsic apoptotic pathway proteins (<a href="#R35" rid="R35" class=" bibr popnode">35</a>) and compared the effects to an MDM2 inhibitor (nutlin-3a) (<a href="#R36" rid="R36" class=" bibr popnode">36</a>). As shown in <a href="/pmc/articles/PMC6279493/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4B</span></a>, AMG 900 increased total p53 and cl-caspase-3 protein levels with negligible changes in MDM2, p21, full-length Bcl-2, Mcl-1, Bcl-xL, and Bax protein levels. Notably, we detected a 23-kDa Bcl-2 protein product that mirrored the induction profile of cl-caspase-3 protein. Bcl-2 can convert from a full-length pro-survival protein to a lower molecular weight (LMW) form that is pro-apoptotic (<a href="#R37" rid="R37" class=" bibr popnode">37</a>). The antibody used in our studies recognizes Bcl-2 peptide 41 to 54 a.a., that is downstream from two caspase cleavage sites (Asp-31, Asp-34); cleavage at these sites generates ~23-kDa protein product. Addition of caspase inhibitors (Z-VAD-fmk, Z-DEVD-fmk) attenuated the anti-proliferative effects of AMG 900 by ~2.5-fold relative to AKI treatment alone, and partially blocked apoptosis and Bcl-2 protein cleavage (<a href="/pmc/articles/PMC6279493/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4C and D</span></a>, <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S5A and B</a>). To examine the effects of AMG 900 on mitochondrial membrane (MM) integrity, we performed JC-1 coupled annexin-V analysis (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S6</a>). In healthy mitochondria, JC-1 dye forms aggregates with orange-red fluorescence emission, during apoptosis, depolarization of the MM results in monomeric JC-1 with a green fluorescence emission profile (<a href="#R38" rid="R38" class=" bibr popnode">38</a>). Treatment with AMG 900 increased the annexin-V population by 7-fold and decreased annexin-V positive JC-1 red fluorescence intensity by 5-fold, in agreement with cells undergoing apoptosis with de-energized MMs (<a href="/pmc/articles/PMC6279493/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4E</span></a>). Together, our results show that inhibition of aurora-B activity by AMG 900 in MOLM-13 cells leads to an increase in polyploidy and centrosome number, activation of p53 pathway without p21 induction, and increase in cell lethality mediated in part by the intrinsic apoptotic pathway.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC6279493/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140653336862560"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6279493_nihms-1508729-f0004.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1508729-f0004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6279493/bin/nihms-1508729-f0004.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140653336862560"><a target="object" rel="noopener" href="/pmc/articles/PMC6279493/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC6279493/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4.</a></div><!--caption a7--><div class="caption"><p id="P35">Inhibition of aurora-B activity by AMG 900 leads to polyploidization associated with extra centrosomes, induction of apoptosis, and Bcl-2 cleavage in MOLM-13 cells. <strong>A,</strong> Cells were treated with AMG 900 at 10 nmol/L or DMSO for 48 hours. Representative confocal images of treated mitotic cells stained with p-histone H3 (<em>red</em>) and pericentrin (<em>green</em>) antibodies and DAPI (<em>blue</em>) (magnification x600). <strong>B,</strong> Cells treated with AMG 900 at 33 nmol/L, nutlin-3a at 2.5 &#x003bc;mol/L, or DMSO for 24 and 48 hours. Western blot analysis showing protein expression of total p53, MDM2, p21, cl-caspase-3, Bax, Bcl-2, Mcl-1, Bcl-xL, and &#x003b2;-actin. Arrows indicate specific target protein band. <strong>C</strong> and <strong>D,</strong> Cells pre-incubated &#x000b1; caspase inhibitors (Z-VAV-fmk, Z-DEVD-fmk) at 10 &#x003bc;mol/L for 2 hours before treatment with AMG 900 at 33 nmol/L or DMSO for 48 hours. Cell count and Western blot analysis. <strong>C,</strong> Cell count represented as POC (mean &#x000b1; SD). <strong>D,</strong> Protein expression profile of cl-caspase-3, Bax, Bcl-2, and &#x003b2;-actin. <strong>E,</strong> Cells treated with AMG 900 at 33 nmol/L or DMSO for 48 hours. Annexin-V/JC-1 analysis. Measurement of annexin-V positivity percentage (left graph, mean &#x000b1; SD) and JC-1 dye red mean fluorescence intensity (MFI) for AMG 900 treated annexin-V negative and positive populations (right graph, mean &#x000b1; SD).</p></div></div></div></div><div id="S15" class="sec"><h3 id="S15title">AMG 900 blocks proliferation of primary HBMNCs without inducing polyploidization.</h3><p id="P20" class="p p-first-last">In clinical studies, the most frequently observed adverse event with AKIs has been on-target myelotoxicity, particularly neutropenia (<a href="#R13" rid="R13" class=" bibr popnode">13</a>&#x02013;<a href="#R15" rid="R15" class=" bibr popnode">15</a>, <a href="#R29" rid="R29" class=" bibr popnode">29</a>). To test the activity of AMG 900 on bone marrow suppression <em>in vitro</em>, we evaluated cultured HBMNCs that express granulocyte markers CD15<sup>+</sup>/CD11b<sup>-</sup> (early myelocytes) and CD15<sup>+</sup>/CD11b<sup>+</sup> (myelocytes to segmented granulocytes) (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S7A</a>). We treated HBMNC cultures with AMG 900 or AZD1152-hQPA for 48 hours and observed an increase in cell death (subG<sub>1</sub>) and a dose-dependent decrease in proliferation (BrdUrd uptake) with EC<sub>50</sub> values similar to their potencies against AML cells (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S7B</a>). To understand the potential recovery profile of normal cells after AKI washout, we shortened the duration of treatment to 24 hours and used anti-mitotic docetaxel as a cytotoxic comparator. In contrast to docetaxel, HBMNCs treated with AZD1152-hQPA or AMG 900 showed and improved recovery proliferation profile by 48 hours after compound washout, where AKIs were comparable to DMSO-treated cells (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S7C and S7D</a>). No substantial accumulation of &#x0003e; 4N DNA content bone marrow cells was observed after treatment with AMG 900, suggesting pre- and/or post-mitotic mechanism (s) exist that prevent bulk polyploidization.</p></div><div id="S16" class="sec sec-last"><h3 id="S16title">AMG 900 reduces tumor burden and inhibits [<sup>18</sup>F]FLT uptake in the skeleton of mice bearing MOLM-13-Luc xenografts. </h3><p id="P21" class="p p-first">To examine the anti-proliferative effects of AMG 900 <em>in vivo</em>, we used a systemic AML model that closely mimics disease dissemination into the skeleton tissues of mice bearing MOLM-13 cells expressing luciferase (<a href="#R31" rid="R31" class=" bibr popnode">31</a>). In addition, we utilized [<sup>18</sup>F]FLT-PET/CT imaging as a noninvasive method of monitoring cell proliferation and drug response (<a href="#R39" rid="R39" class=" bibr popnode">39</a>).</p><p id="P22">Nine days post-tumor implantation, mice were orally administered vehicle or AMG 900 using two dosing schedules (consecutive daily dosing for four days at 22 mg/kg or seven days at 12.6 mg/kg). Mice were imaged for luciferase activity and [<sup>18</sup>F]FLT uptake before initiating treatment (baseline) and at multiple time points after the cessation of AMG 900 treatment as outlined in the study scheme in <a href="/pmc/articles/PMC6279493/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5A</span></a>. As measured by whole body bioluminescence, mice treated with AMG 900 using either dose schedule showed significant anti-tumor activity across study time points relative to vehicle-treated group [tumor growth inhibition 86&#x02013;90% and 94%, <em>P</em> &#x0003c; .0001 (days 6 and 9); 95%, <em>P</em> &#x0003c; 0.02 (day 12)] (<a href="/pmc/articles/PMC6279493/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5B</span></a>). Because of the aggressive nature of the MOLM-13 systemic model, animals with either hind-limb paralysis or significant body weight loss were euthanized. On average, mice maintained &#x02265; 90% of their initial body weight in all treatment groups, one animal from each treatment group died on study by day 19 post-tumor implantation (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. S8</a>). We removed the vehicle-treated group from study on day 19 and the AMG 900-treated groups on day 23. At the end of the study, we assessed mouse femurs for tumor burden by FC, using a DNA content fitting algorithm to quantify the ratio of mouse diploid cells to human aneuploid AML cells (<a href="/pmc/articles/PMC6279493/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5C and D</span></a>). Relative to vehicle-treated group, AMG 900 significantly reduced the MOLM-13 cell fraction in the marrow (<em>P</em> &#x02264; 0.0002) (<a href="/pmc/articles/PMC6279493/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5D</span></a>), with 7-day schedule reducing tumor burden to a greater degree than the 4-day schedule (<em>P</em> = 0.0152).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC6279493/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140653340471168"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6279493_nihms-1508729-f0005.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1508729-f0005.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6279493/bin/nihms-1508729-f0005.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140653340471168"><a target="object" rel="noopener" href="/pmc/articles/PMC6279493/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC6279493/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Figure 5.</a></div><!--caption a7--><div class="caption"><p id="P36">Anti-leukemia activity of AMG 900 in a systemic MOLM-13 tumor xenograft model. Mice bearing established MOLM-13-Luc tumors were orally administered vehicle, AMG 900 at 12.6 mg/kg for 7 days or 22 mg/kg for 4 days (n = 10 per group). <strong>A,</strong> Outline of AMG 900 treatment and biomarker assessment schedule. Whole body BLI was recorded on days 1, 6, 9, 12, 15 (<em>blue</em>, &#x025b2;). [<sup>18</sup>F]FLT-PET/CT measurements were determined the day before treatment (D-1, baseline), and on days 5, 8, 11, and 14 (<em>red</em>, &#x025b2;). Bone marrow (BM) aspirates were collected at study termination [vehicle (day 12) and AMG 900 (day 15)]. <strong>B,</strong> Tumor burden was determined by BLI (mean &#x000b1; SE) for vehicle (<em>black</em>, &#x025cf;, n = 9 on day 12), AMG 900 at 12.6 mg/kg (<em>blue</em>, &#x025a0;, n = 9 on day 12), and AMG 900 at 22 mg/kg (<em>red</em>, &#x025a0;, n = 9 on day 12) groups. Removed one animal from each group due to toxicity by day 12. Entire vehicle group was removed on day 12 due to morbidity. Statistical significance determined for AMG 900 groups versus vehicle on days 6, 9, and 12 (*<em>P</em> &#x0003c; 0.0001, <sup>+</sup><em>P</em> &#x0003c; 0.02). <strong>C</strong> and <strong>D,</strong> Tumor burden measured in femur BM aspirates by DNA content analysis. <strong>C,</strong> Representative fitted DNA content profiles from each treatment group, mouse BM (<em>red</em>) and MOLM-13-Luc (<em>yellow</em>) cell populations (detected G<sub>1</sub> and G<sub>2</sub> peaks, &#x025b2;). <strong>D,</strong> Percentage of tumor to BM cell population based on DNA content (mean &#x000b1; SE). Statistical significance determined for AMG 900 22 mg/kg (n = 9) and 12.6 mg/kg (n = 7) groups versus vehicle (n = 7) (<em>P</em> &#x02264; 0.0002). <strong>E</strong> and <strong>F,</strong> [<sup>18</sup>F]FLT-PET/CT imaging of skeleton tissue. [<sup>18</sup>F]FLT signal was measured at baseline (1 day before treatment) and on days 5, 8, 11, and 14. <strong>E,</strong> Representative images of FLT signal at baseline, and day 5 and 8 post-treatment with AMG 900 at 22 mg/kg or vehicle for 4 days. [<sup>18</sup>F]FLT signal suppression (<em>arrow</em>) and [<sup>18</sup>F]FLT flare (<em>arrowhead</em>) indicated for AMG 900 treatment on day 5 and 8, respectively. <strong>F,</strong> Skeleton [<sup>18</sup>F]FLT signal measured as percentage %ID/g (mean &#x000b1; SE). Statistical significance determined for AMG 900 groups versus vehicle (*<em>P</em> &#x0003c; 0.0001, n = 9 to 10 per group).</p></div></div></div><p id="P23" class="p p-last">The combined approach of PET/CT offers the capability of high-resolution 3D imaging of skeletal tissue to measure and report [<sup>18</sup>F]FLT signal specifically in bone as the percentage injected dose per gram of tissue (%ID/g). Mice were administered FLT radiotracer at baseline (one day before treatment) and on days 5, 8, 11, and 14 after the start of treatment (<a href="/pmc/articles/PMC6279493/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5E and F</span></a>). Administration of AMG 900 on 4-day and 7-day schedules significantly inhibited skeletal [<sup>18</sup>F]FLT uptake measured on day 5 [22 mg/kg AMG 900 = 2.2 %ID/g &#x000b1; 0.08; vehicle = 3.7 %ID/g &#x000b1;0.23 (<em>P</em> &#x0003c; 0.0001)] and day 8 [12.6 mg/kg AMG 900 = 2.8 %ID/g &#x000b1; 0.4; vehicle = 5.2 %ID/g &#x000b1; 0.2 (<em>P</em> &#x0003c; 0.0001)], respectively. Interestingly, both AMG 900 schedules resulted in a [<sup>18</sup>F]FLT flare event measured four days after treatment cessation (<a href="/pmc/articles/PMC6279493/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5E</span></a>, noted by the arrowheads). Skeletal [<sup>18</sup>F]FLT signal decreased within three days after the initial flare event, suggesting the flare may have resulted from a transient pulse of proliferation associated with bone marrow recovery (<a href="#R40" rid="R40" class=" bibr popnode">40</a>) or alternatively, may have resulted from a drug induced cell-cycle synchronization of remaining viable cancer cells.</p></div></div><div id="S17" class="tsec sec"><h2 class="head no_bottom_margin" id="S17title">Discussion</h2><p id="P24" class="p p-first">Despite recent advances in our understanding of AML molecular heterogeneity and pathogenesis (<a href="#R2" rid="R2" class=" bibr popnode">2</a>), new-targeted treatment strategies have largely failed at improving overall survival over standard chemotherapy. In this report, AMG 900 distinguished itself as the most potent anti-leukemic agent across a panel of diverse AML cell lines compared against two AK isoform-selective inhibitors and two classic AML drugs. We established the primary effects of AMG 900 on AML cells resulted in suppression of p-histone H3, polyploidization and/or apoptosis with cellular effects mirroring that of AZD1152-hQPA, indicating inhibition of aurora-B as the dominant driver of anti-leukemic activity. Suppression of p-histone H3 immunoreactivity in AML or normal proliferating cells by AMG 900 may serve as a robust pharmacodynamic marker for monitoring aurora-B inhibition <em>in vivo</em> (<a href="#R41" rid="R41" class=" bibr popnode">41</a>), whereas accurately measuring aurora-A inhibition <em>in vivo</em> remains a challenge for the field (<a href="#R42" rid="R42" class=" bibr popnode">42</a>). Our cell line data supports that MLN8054 has a more complex concentration-dependent mode-of-action, either by activating SAC through selective inhibition of aurora-A, or by SAC silencing through dual AK inhibition at higher micromolar concentrations. Based on our current study, we cannot definitively conclude that dual AK inhibition is more efficient at killing AML cells than isoform-selective AK inhibition. However, in contrast to isoform-specific AKIs, dual AK inhibition by AMG 900 reduces the likelihood of resistance driven by target-modifying mutations, as both mitotic genes are essential for cell division (<a href="#R25" rid="R25" class=" bibr popnode">25</a>). Multiple other factors can contribute to drug resistance including elevated expression of P-gp, which in elderly AML patients is strongly associated with negative outcomes (<a href="#R21" rid="R21" class=" bibr popnode">21</a>, <a href="#R43" rid="R43" class=" bibr popnode">43</a>). Unlike the case with AZD1152-hQPA, cell surface expression of P-gp on AML cells did not confer resistance to AMG 900. Clinically, selection of AML patients based on P-gp expression level is one biomarker approach to assess the utility of AMG 900 at combating drug-efflux mediated resistance, particularly in a relapse setting. Conversely, AMG 900 could negatively impact cycling immature hematopoietic progenitor cells expressing P-gp and BCRP1.</p><p id="P25">A subset of bone marrow proliferative disorders such as AMKL and PMF are characterized by defects in megakaryocyte differentiation. AMG 900-treatment of AMKL and <em>Jak2</em><sup>V617F</sup> mutant cells induced parallel increases in DNA ploidy, cytoplasmic volume, and expression of CD41/CD42, all three phenotypes associated with megakaryocyte maturation. Admittedly, this same assessment should be expanded to include AZD1152-hQPA to determine whether selective aurora-B and dual AK inhibition induce similar hallmarks of megakaryocyte maturation (<a href="#R16" rid="R16" class=" bibr popnode">16</a>). Induction of differentiation with all-<em>trans</em> retinoic acid is a successful strategy for treating acute promeylocytic leukemia (<a href="#R44" rid="R44" class=" bibr popnode">44</a>), whether this approach can be efficacious with induction of polyploidization (<a href="#R18" rid="R18" class=" bibr popnode">18</a>) is actively under investigation with alisertib in AMKL and PMF patients.</p><p id="P26">In the next phase of our <em>in vitro</em> studies, we determined that AMG 900 combined with LDAC either enhanced (HEL, MOLM-13) or attenuated cell killing (GDM-1, U937). The observation that <em>TP53</em><sup>WT</sup> GDM-1 cells showed a strong cell arrest response after AMG 900 treatment suggests p21 protein induction promotes an antagonistic interaction with Ara-C in terms of lethality. Evaluating AK inhibition in combination with Ara-C in a larger panel of AML lines and primary AMLs representing diverse FAB subtypes and genotypes is an appropriate next step to better define the response differences observed in our study and to elucidate the molecular underpinnings driving enhanced cell killing. In a phase-1 AML study with AMG 900, baseline expression levels of select mitotic genes (<em>AURKA</em>, <em>AURKB</em>, <em>BIRC5</em>, <em>CCNB1</em>, <em>CDC2</em>, <em>TTK</em>) were evaluated in 24 patients as exploratory biomarkers. Of note, three CRi responders to AMG 900 all showed elevated expression of mitotic genes at baseline (<a href="#R29" rid="R29" class=" bibr popnode">29</a>). While these results are interesting, additional studies are needed due to the small sample size. One unanticipated finding from our <em>in vitro</em> studies was the detection of a LMW-form of Bcl-2 protein after AMG 900 treatment in MOLM-13 cells. Cleavage of Bcl-2 is believed to inactivate its pro-survival function, consistent with our observation that peptide caspase inhibitors attenuated the apoptotic response of AMG 900 noted by the concomitant drop in active-caspase-3 and LMW-form of Bcl-2 protein levels. We detected no changes in the ratio of Bcl-2 to Bax protein expression with AMG 900, which was previously reported to be positive predictor of pro-apoptotic response in AML lines treated with pan-AKI VX-680 (<a href="#R35" rid="R35" class=" bibr popnode">35</a>). In this report, we did not directly address the cell fate of cycling polyploid AML cells harboring extra centrosomes after AKI withdrawal. Given that SAC silencing by AMG 900 leads to exit from mitosis without division, the likelihood of a mitotic catastrophe event with AKI present is low. However, upon SAC restoration after AMG 900 wash out, polyploid AML cells that transition through mitosis are expected to trigger lethal multipolar cell division and/or cellular senescence in the next interphase.</p><p id="P27">On-mechanism toxicity to normal proliferating tissues has hindered clinical development of small molecule inhibitors targeting mitotic kinases and kinesins (<a href="#R45" rid="R45" class=" bibr popnode">45</a>). Consistent with this anti-mitotic class effect, AMG 900 induced cytotoxicity on HBMNCs in culture; however, we did observe an improved time-to-recovery profile after AMG 900 washout relative to classic anti-mitotic agent docetaxel. Several factors have the potential to influence efficacy/toxicity profile such as individual AKI drug-like properties, dose scheduling, route of administration, and formulation. One recent approach aimed at improving the effectiveness of AZD1152-hQPA used a nanoparticle formulation and an alternative dose schedule to successfully demonstrate durable regressions in AML xenograft models with lower toxicity (<a href="#R46" rid="R46" class=" bibr popnode">46</a>); this same strategy is now in clinical testing with AZD1152-hQPA in AML and myelodysplastic syndrome patients (<a id="__tag_738135337" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03217838" ref="reftype=extlink-clinical-trial&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03217838","term_id":"NCT03217838"}}</span>NCT03217838</a>).</p><p id="P28">In line with our <em>in vitro</em> results, AMG 900 demonstrates robust anti-leukemia activity in an aggressive MOLM-13 systemic xenograft model, in which tumor burden was determined by whole body bioluminescence and AML cell dissemination in skeletal tissue. A single cycle of AMG 900 treatment using two clinically relevant schedules (4-day and 7-day) (<a href="#R29" rid="R29" class=" bibr popnode">29</a>) resulted in significant tumor growth inhibition (&#x0003e;85% TGI) by BLI. We also observed a reduction in tumor burden in mouse femurs, where the 7-day schedule appeared to be more effective at clearing AML cells from the bone. Additional studies will be required using multiple cycles of AMG 900 treatment in a less aggressive AML xenograft model to assess anti-leukemia durability. In order to correlate the anti-tumor effects of AMG 900 more directly, we assessed active DNA replication (S-phase) fraction using radiotracer [<sup>18</sup>F]FLT-PET in skeletal tissue. Factors that influence [<sup>18</sup>F]FLT-PET signal output after AKI treatment may include differences in proliferation rates between bone marrow and AML cells, thymidine kinase 1 expression, and the level of polyploidization (<a href="#R40" rid="R40" class=" bibr popnode">40</a>, <a href="#R47" rid="R47" class=" bibr popnode">47</a>). With those stated factors, we clearly demonstrated AMG 900 reduced skeletal [<sup>18</sup>F]FLT signal during the treatment phase followed by an [<sup>18</sup>F]FLT flare event after treatment cessation, which may have resulted from bone marrow recovery and/or AML cells re-entering S-phase. Based on these data, [<sup>18</sup>F]FLT-PET imaging could be used to further optimize AMG 900 dose scheduling and explore multidrug combinations. Importantly from a therapeutic perspective, Ara-C is a cell-cycle phase specific nucleoside that kills cells in S-phase (<a href="#R48" rid="R48" class=" bibr popnode">48</a>), therefore one could hypothesize that induction of an AMG 900 [<sup>18</sup>F]FLT flare event followed by LDAC may prime leukemia cells for maximal killing and thereby improve durability of response.</p><p id="P29" class="p p-last">In summary, we provide evidence that AMG 900 has potent anti-leukemia activity on a panel of AML lines and that it can cooperatively promote enhanced cell killing in combination with LDAC. Cellular effects of AMG 900 were similar to AZD1152-hQPA, with differences in activity due to drug-efflux and kinase specificity. We discovered AMG 900 triggers maturation of AMKL and <em>Jak2</em><sup>V617F</sup> cells, suggesting it can act as a differentiation inducer. Our work provides an initial framework in which AMG 900 can serve as a best-in-class pan-AKI for further exploration of the effects of AKIs on the interconnected p53/apoptotic/mitotic signaling networks in AML. Lastly, we highlight the <em>in vivo</em> activity of AMG 900 in a systemic AML model and the utility of [<sup>18</sup>F]FLT-PET/CT imaging for monitoring drug action.</p></div><div id="SM1" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="SM1title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>1</h4><div class="sup-box half_rhythm" id="d36e846"><a href="/pmc/articles/PMC6279493/bin/NIHMS1508729-supplement-1.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(2.8M, docx)</sup></div></div></div><div id="S18" class="tsec sec"><h2 class="head no_bottom_margin" id="S18title">Acknowledgments</h2><div class="sec"><p id="P30">The authors thank individuals on AMG 900 project and specifically Stephanie Geuns-Meyer, Kathleen Keegan, Gregory Friberg, Erick Gamelin, Richard Kendall, Peter Pieslor, and Florian Vogl. We thank Ann Mullally at Brigham and Women&#x02019;s Hospital/Harvard Medical School for providing the <em>Jak2</em><sup>V617F</sup> mice. This work was supported in part by a grant from the NIH (HL112792) to JDC. We would also like to acknowledge the team from Molecular Imaging Inc. and inviCRO Inc. for conducting the <em>in vivo</em> imaging studies.</p></div></div><div id="fn-group-a.j.b" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.j.btitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN1"><p id="P31" class="p p-first-last">Disclosure of Potential Conflicts of Interest. M. Payton, K. Cheung, W. Wayne, K. Hanestad, G. Juan, and A. Coxon are current or former full-time employees of Amgen Inc. and have owned stock in Amgen Inc. at the time this work was conducted. No potential conflicts of interest were disclosed by the other authors.</p></p></div></div><div id="ref-list-a.j.c" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.j.ctitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="mixed-citation">Siegel RL, Miller KD, Jemal A. <span class="ref-title">Cancer statistics, 2015</span>. <span class="ref-journal">CA: A Cancer J for Clinicians</span>. 2015;<span class="ref-vol">65</span>:5&#x02013;29. [<a href="https://pubmed.ncbi.nlm.nih.gov/25559415" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=CA:+A+Cancer+J+for+Clinicians&amp;title=Cancer+statistics,+2015&amp;author=RL+Siegel&amp;author=KD+Miller&amp;author=A+Jemal&amp;volume=65&amp;publication_year=2015&amp;pages=5-29&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="mixed-citation">Dohner H, Weisdorf DJ, Bloomfield CD. <span class="ref-title">Acute Myeloid Leukemia</span>. <span class="ref-journal">N Engl. J Med</span>
2015;<span class="ref-vol">373</span>:1137&#x02013;51. [<a href="https://pubmed.ncbi.nlm.nih.gov/26376137" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl.+J+Med&amp;title=Acute+Myeloid+Leukemia&amp;author=H+Dohner&amp;author=DJ+Weisdorf&amp;author=CD+Bloomfield&amp;volume=373&amp;publication_year=2015&amp;pages=1137-51&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="mixed-citation">Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. 
<span class="ref-title">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span>. <span class="ref-journal">N Engl. J Med</span>. 2017;<span class="ref-vol">377</span>:454&#x02013;64. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5754190/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28644114" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl.+J+Med&amp;title=Midostaurin+plus+chemotherapy+for+acute+myeloid+leukemia+with+a+FLT3+mutation&amp;author=RM+Stone&amp;author=SJ+Mandrekar&amp;author=BL+Sanford&amp;author=K+Laumann&amp;author=S+Geyer&amp;volume=377&amp;publication_year=2017&amp;pages=454-64&amp;pmid=28644114&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="mixed-citation">Laubach J, Rao AV. <span class="ref-title">Current and emerging strategies for the management of acute myeloid leukemia in the elderly</span>. <span class="ref-journal">The Oncologist</span>
2008;<span class="ref-vol">13</span>:1097&#x02013;1108. [<a href="https://pubmed.ncbi.nlm.nih.gov/18922830" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Oncologist&amp;title=Current+and+emerging+strategies+for+the+management+of+acute+myeloid+leukemia+in+the+elderly&amp;author=J+Laubach&amp;author=AV+Rao&amp;volume=13&amp;publication_year=2008&amp;pages=1097-1108&amp;pmid=18922830&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="mixed-citation">Lens SM, Voest EE, Medema RH. <span class="ref-title">Shared and separate functions of polo-like kinases and aurora kinases in cancer</span>. <span class="ref-journal">Nat Rev Cancer</span>. 2010;<span class="ref-vol">10</span>:825&#x02013;41. [<a href="https://pubmed.ncbi.nlm.nih.gov/21102634" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Shared+and+separate+functions+of+polo-like+kinases+and+aurora+kinases+in+cancer&amp;author=SM+Lens&amp;author=EE+Voest&amp;author=RH+Medema&amp;volume=10&amp;publication_year=2010&amp;pages=825-41&amp;pmid=21102634&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="mixed-citation">Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gardara DR
et al. 
<span class="ref-title">Aurora kinases as anticancer drug targets</span>. <span class="ref-journal">Clin Cancer Res</span>
2008;<span class="ref-vol">14</span>:1639&#x02013;48. [<a href="https://pubmed.ncbi.nlm.nih.gov/18347165" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Aurora+kinases+as+anticancer+drug+targets&amp;author=O+Gautschi&amp;author=J+Heighway&amp;author=PC+Mack&amp;author=PR+Purnell&amp;author=PN+Lara&amp;volume=14&amp;publication_year=2008&amp;pages=1639-48&amp;pmid=18347165&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="mixed-citation">Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y
et al. 
<span class="ref-title">A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia</span>. <span class="ref-journal">Mol Cancer Ther</span>
2007;<span class="ref-vol">6</span>:1851&#x02013;57. [<a href="https://pubmed.ncbi.nlm.nih.gov/17541033" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=A+novel+treatment+strategy+targeting+Aurora+kinases+in+acute+myelogenous+leukemia&amp;author=T+Ikezoe&amp;author=J+Yang&amp;author=C+Nishioka&amp;author=T+Tasaka&amp;author=A+Taniguchi&amp;volume=6&amp;publication_year=2007&amp;pages=1851-57&amp;pmid=17541033&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="mixed-citation">Goldenson B, Crispino JD. <span class="ref-title">The aurora kinases in cell cycle and leukemia</span>. <span class="ref-journal">Oncogene</span>
2015;<span class="ref-vol">34</span>:537&#x02013;45. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4167158/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24632603" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The+aurora+kinases+in+cell+cycle+and+leukemia&amp;author=B+Goldenson&amp;author=JD+Crispino&amp;volume=34&amp;publication_year=2015&amp;pages=537-45&amp;pmid=24632603&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="mixed-citation">Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. 
<span class="ref-title">Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase</span>. <span class="ref-journal">PNAS</span>
2007;<span class="ref-vol">104</span>:4106&#x02013;11. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1820716/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17360485" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PNAS&amp;title=Antitumor+activity+of+MLN8054,+an+orally+active+small-molecule+inhibitor+of+Aurora+A+kinase&amp;author=MG+Manfredi&amp;author=JA+Ecsedy&amp;author=KA+Meetze&amp;author=SK+Balani&amp;author=O+Burenkova&amp;volume=104&amp;publication_year=2007&amp;pages=4106-11&amp;pmid=17360485&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="mixed-citation">Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J
et al. 
<span class="ref-title">MLN8054 and Alisertib (MLN8237): discovery of selective oral Aurora A inhibitors</span>. <span class="ref-journal">ACS Med Chem Letters</span>. 2015;<span class="ref-vol">6</span>:630&#x02013;34. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4468408/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26101564" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=ACS+Med+Chem+Letters&amp;title=MLN8054+and+Alisertib+(MLN8237):+discovery+of+selective+oral+Aurora+A+inhibitors&amp;author=TB+Sells&amp;author=R+Chau&amp;author=JA+Ecsedy&amp;author=RE+Gershman&amp;author=K+Hoar&amp;volume=6&amp;publication_year=2015&amp;pages=630-34&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="mixed-citation">Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J
et al. 
<span class="ref-title">AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo</span>. <span class="ref-journal">Cancer Res</span>
2009;<span class="ref-vol">15</span>;<span class="ref-iss">69</span>:4150&#x02013;58. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2684546/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19366807" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=AZD1152+rapidly+and+negatively+affects+the+growth+and+survival+of+human+acute+myeloid+leukemia+cells+in+vitro+and+in+vivo&amp;author=A+Oke&amp;author=D+Pearce&amp;author=RW+Wilkinson&amp;author=C+Crafter&amp;author=R+Odedra&amp;volume=15&amp;issue=69&amp;publication_year=2009&amp;pages=4150-58&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="mixed-citation">Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M. <span class="ref-title">The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells</span>. <span class="ref-journal">Mol Cancer Ther</span>
2010;<span class="ref-vol">9</span>:661&#x02013;72. [<a href="https://pubmed.ncbi.nlm.nih.gov/20159992" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=The+FLT3+internal+tandem+duplication+mutation+is+a+secondary+target+of+the+aurora+B+kinase+inhibitor+AZD1152-HQPA+in+acute+myelogenous+leukemia+cells&amp;author=M+Grundy&amp;author=C+Seedhouse&amp;author=S+Shang&amp;author=J+Richardson&amp;author=N+Russell&amp;volume=9&amp;publication_year=2010&amp;pages=661-72&amp;pmid=20159992&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="mixed-citation">Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J
et al . <span class="ref-title">An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes</span>. <span class="ref-journal">Leuk Res Reports</span>
2014;<span class="ref-vol">3</span>:58&#x02013;61. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4110881/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25068104" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leuk+Res+Reports&amp;title=An+exploratory+phase+2+study+of+investigational+Aurora+A+kinase+inhibitor+alisertib+(MLN8237)+in+acute+myelogenous+leukemia+and+myelodysplastic+syndromes&amp;author=SL+Goldberg&amp;author=P+Fenaux&amp;author=MD+Craig&amp;author=E+Gyan&amp;author=J+Lister&amp;volume=3&amp;publication_year=2014&amp;pages=58-61&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="mixed-citation">L&#x000f6;wenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N
et al. 
<span class="ref-title">Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia</span>. <span class="ref-journal">Blood</span>
2011;<span class="ref-vol">118</span>:6030&#x02013;36. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4186639/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21976672" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Phase+1/2+study+to+assess+the+safety,+efficacy,+and+pharmacokinetics+of+barasertib+(AZD1152)+in+patients+with+advanced+acute+myeloid+leukemia&amp;author=B+L&#x000f6;wenberg&amp;author=P+Muus&amp;author=G+Ossenkoppele&amp;author=P+Rousselot&amp;author=JY+Cahn&amp;volume=118&amp;publication_year=2011&amp;pages=6030-36&amp;pmid=21976672&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="mixed-citation">Kantarjian HM, Martinelli G, Jabbour EJ, Quint&#x000e1;s&#x02010;Cardama A, Ando K, Bay JO
et al . <span class="ref-title">Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low&#x02010;dose cytosine arabinoside in elderly patients with acute myeloid leukemia</span>. <span class="ref-journal">Cancer</span>. 2013;<span class="ref-vol">119</span>:2611&#x02013;9. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4132839/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23605952" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Stage+I+of+a+phase+2+study+assessing+the+efficacy,+safety,+and+tolerability+of+barasertib+(AZD1152)+versus+low&#x02010;dose+cytosine+arabinoside+in+elderly+patients+with+acute+myeloid+leukemia&amp;author=HM+Kantarjian&amp;author=G+Martinelli&amp;author=EJ+Jabbour&amp;author=A+Quint&#x000e1;s&#x02010;Cardama&amp;author=K+Ando&amp;volume=119&amp;publication_year=2013&amp;pages=2611-9&amp;pmid=23605952&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="mixed-citation">Wen QJ, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z
et al. 
<span class="ref-title">Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL</span>. <span class="ref-journal">Cell</span>. 2012;<span class="ref-vol">150</span>:575&#x02013;89. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3613864/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22863010" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Identification+of+regulators+of+polyploidization+presents+therapeutic+targets+for+treatment+of+AMKL&amp;author=QJ+Wen&amp;author=B+Goldenson&amp;author=SJ+Silver&amp;author=M+Schenone&amp;author=V+Dancik&amp;volume=150&amp;publication_year=2012&amp;pages=575-89&amp;pmid=22863010&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="mixed-citation">Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, et al. 
<span class="ref-title">Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition</span>. <span class="ref-journal">Nat Med</span>
2015;<span class="ref-vol">21</span>:1473&#x02013;80. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4674320/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26569382" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Targeting+megakaryocytic-induced+fibrosis+in+myeloproliferative+neoplasms+by+AURKA+inhibition&amp;author=QJ+Wen&amp;author=Q+Yang&amp;author=B+Goldenson&amp;author=S+Malinge&amp;author=T+Lasho&amp;volume=21&amp;publication_year=2015&amp;pages=1473-80&amp;pmid=26569382&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="mixed-citation">Krause DS, Crispino JD. <span class="ref-title">Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia</span>. <span class="ref-journal">Clin Cancer Res</span>
2013;<span class="ref-vol">19</span> :6084&#x02013;88. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3836832/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23963861" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Molecular+pathways:+induction+of+polyploidy+as+a+novel+differentiation+therapy+for+leukemia&amp;author=DS+Krause&amp;author=JD+Crispino&amp;volume=19&amp;publication_year=2013&amp;pages=6084-88&amp;pmid=23963861&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="mixed-citation">Wiseman DH, Greystoke BF, Somervaille TCP. <span class="ref-title">The variety of leukemia stem cells in myeloid malignancy</span>. <span class="ref-journal">Oncogene</span>
2014;<span class="ref-vol">33</span>: 3091&#x02013;98. [<a href="https://pubmed.ncbi.nlm.nih.gov/23831573" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The+variety+of+leukemia+stem+cells+in+myeloid+malignancy&amp;author=DH+Wiseman&amp;author=BF+Greystoke&amp;author=TCP+Somervaille&amp;volume=33&amp;publication_year=2014&amp;pages=3091-98&amp;pmid=23831573&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="mixed-citation">Stiehl T, Baran N, Ho AD, Marciniak-Czochra A. <span class="ref-title">Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: a model to predict patient survival</span>. <span class="ref-journal">Cancer Res</span>
2015;<span class="ref-vol">75</span>:940&#x02013;49. [<a href="https://pubmed.ncbi.nlm.nih.gov/25614516" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Cell+division+patterns+in+acute+myeloid+leukemia+stem-like+cells+determine+clinical+course:+a+model+to+predict+patient+survival&amp;author=T+Stiehl&amp;author=N+Baran&amp;author=AD+Ho&amp;author=A+Marciniak-Czochra&amp;volume=75&amp;publication_year=2015&amp;pages=940-49&amp;pmid=25614516&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="mixed-citation">Xia CQ, Smith PG. <span class="ref-title">Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation</span>. <span class="ref-journal">Mol Pharm</span>
2012;<span class="ref-vol">82</span>:1008&#x02013;21. [<a href="https://pubmed.ncbi.nlm.nih.gov/22826468" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Pharm&amp;title=Drug+efflux+transporters+and+multidrug+resistance+in+acute+leukemia:+therapeutic+impact+and+novel+approaches+to+mediation&amp;author=CQ+Xia&amp;author=PG+Smith&amp;volume=82&amp;publication_year=2012&amp;pages=1008-21&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="mixed-citation">Grundy M, Seedhouse C, Russell NH, Pallis M. <span class="ref-title">P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA</span>. <span class="ref-journal">BMC Cancer</span>. 2011;<span class="ref-vol">11</span> :254.1&#x02013;13. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3146447/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21679421" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Cancer&amp;title=P-glycoprotein+and+breast+cancer+resistance+protein+in+acute+myeloid+leukaemia+cells+treated+with+the+aurora-B+kinase+inhibitor+barasertib-hQPA&amp;author=M+Grundy&amp;author=C+Seedhouse&amp;author=NH+Russell&amp;author=M+Pallis&amp;volume=11&amp;publication_year=2011&amp;pages=254.1-13&amp;pmid=21679421&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="mixed-citation">Girdler F, Sessa F, Patercoli S, Villa F, Musacchio A, Taylor S. <span class="ref-title">Molecular basis of drug resistance in aurora kinases</span>. <span class="ref-journal">Chem &#x00026; Biol</span>
2008:<span class="ref-vol">23</span>;<span class="ref-iss">15</span>:552&#x02013;62. [<a href="https://pubmed.ncbi.nlm.nih.gov/18559266" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Chem+&#x00026;+Biol&amp;title=Molecular+basis+of+drug+resistance+in+aurora+kinases&amp;author=F+Girdler&amp;author=F+Sessa&amp;author=S+Patercoli&amp;author=F+Villa&amp;author=A+Musacchio&amp;volume=23&amp;issue=15&amp;publication_year=2008&amp;pages=552-62&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="mixed-citation">Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. 
<span class="ref-title">Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines</span>. <span class="ref-journal">Cancer Res</span>
2010;<span class="ref-vol">70</span>:9846&#x02013;54. [<a href="https://pubmed.ncbi.nlm.nih.gov/20935223" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Preclinical+evaluation+of+AMG+900,+a+novel+potent+and+highly+selective+pan-aurora+kinase+inhibitor+with+activity+in+taxane-resistant+tumor+cell+lines&amp;author=M+Payton&amp;author=TL+Bush&amp;author=G+Chung&amp;author=B+Ziegler&amp;author=P+Eden&amp;volume=70&amp;publication_year=2010&amp;pages=9846-54&amp;pmid=20935223&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="mixed-citation">Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN
et al. 
<span class="ref-title">Discovery of N-(4-(3-(2-aminopyrimidin-4-yl) pyridin-2-yloxy) phenyl)-4-(4-methylthiophen-2-yl) phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines</span>. <span class="ref-journal">J Med Chem</span>
2015;<span class="ref-vol">58</span>:5189&#x02013;207. [<a href="https://pubmed.ncbi.nlm.nih.gov/25970324" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Discovery+of+N-(4-(3-(2-aminopyrimidin-4-yl)+pyridin-2-yloxy)+phenyl)-4-(4-methylthiophen-2-yl)+phthalazin-1-amine+(AMG+900),+a+highly+selective,+orally+bioavailable+inhibitor+of+aurora+kinases+with+activity+against+multidrug-resistant+cancer+cell+lines&amp;author=S+Geuns-Meyer&amp;author=VJ+Cee&amp;author=HL+Deak&amp;author=B+Du&amp;author=BL+Hodous&amp;volume=58&amp;publication_year=2015&amp;pages=5189-207&amp;pmid=25970324&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="mixed-citation">Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB
et al. 
<span class="ref-title">AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models</span>. <span class="ref-journal">Mol Cancer Ther</span>
2013;<span class="ref-vol">12</span>:2356&#x02013;66. [<a href="https://pubmed.ncbi.nlm.nih.gov/23990115" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=AMG+900,+a+small-molecule+inhibitor+of+aurora+kinases,+potentiates+the+activity+of+microtubule-targeting+agents+in+human+metastatic+breast+cancer+models&amp;author=TL+Bush&amp;author=M+Payton&amp;author=S+Heller&amp;author=G+Chung&amp;author=K+Hanestad&amp;volume=12&amp;publication_year=2013&amp;pages=2356-66&amp;pmid=23990115&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="mixed-citation">Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C
et al. 
<span class="ref-title">AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53</span>. <span class="ref-journal">Breast Cancer Res and Treatment</span>. 2013;<span class="ref-vol">141</span>:397&#x02013;408. [<a href="https://pubmed.ncbi.nlm.nih.gov/24091768" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+and+Treatment&amp;title=AMG+900,+pan-Aurora+kinase+inhibitor,+preferentially+inhibits+the+proliferation+of+breast+cancer+cell+lines+with+dysfunctional+p53&amp;author=O+Kalous&amp;author=D+Conklin&amp;author=AJ+Desai&amp;author=J+Dering&amp;author=J+Goldstein&amp;volume=141&amp;publication_year=2013&amp;pages=397-408&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="mixed-citation">Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS
et al. 
<span class="ref-title">Combining the pan&#x02010;aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer</span>. <span class="ref-journal">Cancer Med</span>
2014;<span class="ref-vol">3</span>:1322&#x02013;35. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4302682/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24989836" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Med&amp;title=Combining+the+pan&#x02010;aurora+kinase+inhibitor+AMG+900+with+histone+deacetylase+inhibitors+enhances+antitumor+activity+in+prostate+cancer&amp;author=CJ+Paller&amp;author=MD+Wissing&amp;author=J+Mendonca&amp;author=A+Sharma&amp;author=E+Kim&amp;volume=3&amp;publication_year=2014&amp;pages=1322-35&amp;pmid=24989836&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="mixed-citation">Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E
et al. 
<span class="ref-title">A phase 1 study of AMG 900, an orally administered pan&#x02010;aurora kinase inhibitor, in adult patients with acute myeloid leukemia</span>. <span class="ref-journal">Am J Hematol</span>
2017;<span class="ref-vol">92</span>:660&#x02013;67. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5925751/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28370201" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hematol&amp;title=A+phase+1+study+of+AMG+900,+an+orally+administered+pan&#x02010;aurora+kinase+inhibitor,+in+adult+patients+with+acute+myeloid+leukemia&amp;author=HM+Kantarjian&amp;author=MW+Schuster&amp;author=N+Jain&amp;author=A+Advani&amp;author=E+Jabbour&amp;volume=92&amp;publication_year=2017&amp;pages=660-67&amp;pmid=28370201&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="mixed-citation">Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. <span class="ref-title">In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative</span>. <span class="ref-journal">Cancer Research</span>. 1993;<span class="ref-vol">53</span>:4595&#x02013;602. [<a href="https://pubmed.ncbi.nlm.nih.gov/8402633" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=In+vitro+and+in+vivo+reversal+of+multidrug+resistance+by+GF120918,+an+acridonecarboxamide+derivative&amp;author=F+Hyafil&amp;author=C+Vergely&amp;author=P+Du+Vignaud&amp;author=T+Grand-Perret&amp;volume=53&amp;publication_year=1993&amp;pages=4595-602&amp;pmid=8402633&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="mixed-citation">Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S
et al. 
<span class="ref-title">Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</span>. <span class="ref-journal">Mol Cancer Ther</span>
2014;<span class="ref-vol">13</span>:880&#x02013;9. [<a href="https://pubmed.ncbi.nlm.nih.gov/24526162" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Preclinical+evaluation+of+AMG+925,+a+FLT3/CDK4+dual+kinase+inhibitor+for+treating+acute+myeloid+leukemia&amp;author=K+Keegan&amp;author=C+Li&amp;author=Z+Li&amp;author=J+Ma&amp;author=M+Ragains&amp;volume=13&amp;publication_year=2014&amp;pages=880-9&amp;pmid=24526162&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="mixed-citation">Szak&#x000e1;cs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. <span class="ref-title">Targeting multidrug resistance in cancer</span>. <span class="ref-journal">Nat Rev Drug Disc</span>
2006;<span class="ref-vol">5</span>:219&#x02013;34. [<a href="https://pubmed.ncbi.nlm.nih.gov/16518375" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Disc&amp;title=Targeting+multidrug+resistance+in+cancer&amp;author=G+Szak&#x000e1;cs&amp;author=JK+Paterson&amp;author=JA+Ludwig&amp;author=C+Booth-Genthe&amp;author=MM+Gottesman&amp;volume=5&amp;publication_year=2006&amp;pages=219-34&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="mixed-citation">Ikezoe T, Yang J, Nishioka C, Yokoyama A. <span class="ref-title">p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells</span>. <span class="ref-journal">Int J Hematol</span>
2010;<span class="ref-vol">91</span>:69&#x02013;77. [<a href="https://pubmed.ncbi.nlm.nih.gov/20013323" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Hematol&amp;title=p53+is+critical+for+the+Aurora+B+kinase+inhibitor-mediated+apoptosis+in+acute+myelogenous+leukemia+cells&amp;author=T+Ikezoe&amp;author=J+Yang&amp;author=C+Nishioka&amp;author=A+Yokoyama&amp;volume=91&amp;publication_year=2010&amp;pages=69-77&amp;pmid=20013323&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="mixed-citation">Chou TC. <span class="ref-title">Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies</span>. <span class="ref-journal">Pharmacological Rev</span>
2006;<span class="ref-vol">58</span>:621&#x02013;81. [<a href="https://pubmed.ncbi.nlm.nih.gov/16968952" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacological+Rev&amp;title=Theoretical+basis,+experimental+design,+and+computerized+simulation+of+synergism+and+antagonism+in+drug+combination+studies&amp;author=TC+Chou&amp;volume=58&amp;publication_year=2006&amp;pages=621-81&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="mixed-citation">Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX. <span class="ref-title">Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia</span>. <span class="ref-journal">Blood</span>
2008;<span class="ref-vol">111</span>:2854&#x02013;65. [<a href="https://pubmed.ncbi.nlm.nih.gov/18160664" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Aurora+kinase+inhibitory+VX-680+increases+Bax/Bcl-2+ratio+and+induces+apoptosis+in+Aurora-A-high+acute+myeloid+leukemia&amp;author=XF+Huang&amp;author=SK+Luo&amp;author=J+Xu&amp;author=J+Li&amp;author=DR+Xu&amp;volume=111&amp;publication_year=2008&amp;pages=2854-65&amp;pmid=18160664&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="mixed-citation">Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T
et al. 
<span class="ref-title">MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy</span>. <span class="ref-journal">Blood</span>
2005;<span class="ref-vol">106</span>:3150&#x02013;9. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1895324/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16014563" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=MDM2+antagonists+induce+p53-dependent+apoptosis+in+AML:+implications+for+leukemia+therapy&amp;author=K+Kojima&amp;author=M+Konopleva&amp;author=IJ+Samudio&amp;author=M+Shikami&amp;author=M+Cabreira-Hansen&amp;volume=106&amp;publication_year=2005&amp;pages=3150-9&amp;pmid=16014563&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="mixed-citation">Fadeel B, Hassan Z, Hellstr&#x000f6;m-Lindberg E, Henter JI, Orrenius S, Zhivotovsky B. <span class="ref-title">Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells</span>. <span class="ref-journal">Leukemia</span>
1999;<span class="ref-vol">13</span>:719&#x02013;28. [<a href="https://pubmed.ncbi.nlm.nih.gov/10374876" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Cleavage+of+Bcl-2+is+an+early+event+in+chemotherapy-induced+apoptosis+of+human+myeloid+leukemia+cells&amp;author=B+Fadeel&amp;author=Z+Hassan&amp;author=E+Hellstr&#x000f6;m-Lindberg&amp;author=JI+Henter&amp;author=S+Orrenius&amp;volume=13&amp;publication_year=1999&amp;pages=719-28&amp;pmid=10374876&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="mixed-citation">Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC 1, <span class="ref-title">but not DiOC6 (3) or rhodamine 123, is a reliable fluorescent probe to assess &#x00394;&#x003a8; changes in intact cells: implications for studies on mitochondrial functionality during apoptosis</span>. <span class="ref-journal">FEBS letters</span>. 1997;<span class="ref-vol">411</span>:77&#x02013;82. [<a href="https://pubmed.ncbi.nlm.nih.gov/9247146" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+letters&amp;title=but+not+DiOC6+(3)+or+rhodamine+123,+is+a+reliable+fluorescent+probe+to+assess+&#x00394;&#x003a8;+changes+in+intact+cells:+implications+for+studies+on+mitochondrial+functionality+during+apoptosis&amp;author=S+Salvioli&amp;author=A+Ardizzoni&amp;author=C+Franceschi&amp;author=A+Cossarizza&amp;author=1+JC&amp;volume=411&amp;publication_year=1997&amp;pages=77-82&amp;pmid=9247146&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="mixed-citation">Vanderhoek M, Juckett MB, Perlman SB, Nickles RJ, Jeraj R. <span class="ref-title">Early assessment of treatment response in patients with AML using [18 F] FLT PET imaging</span>. <span class="ref-journal">Leukemia Res</span>
2011;<span class="ref-vol">35</span>:310&#x02013;6. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3319294/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20832860" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia+Res&amp;title=Early+assessment+of+treatment+response+in+patients+with+AML+using+[18+F]+FLT+PET+imaging&amp;author=M+Vanderhoek&amp;author=MB+Juckett&amp;author=SB+Perlman&amp;author=RJ+Nickles&amp;author=R+Jeraj&amp;volume=35&amp;publication_year=2011&amp;pages=310-6&amp;pmid=20832860&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="mixed-citation">Schelhaas S, Held A, B&#x020ac;aumer N, Viel T, Hermann S, M&#x020ac;uller-Tidow C, Jacobs AH. <span class="ref-title">Preclinical evidence that 3&#x02019;-Deoxy-3&#x02019;-[18F]Fluorothymidine PET can visualize recovery of hematopoiesis after gemcitabine chemotherapy</span>. <span class="ref-journal">Cancer Res</span>
2016:<span class="ref-vol">76</span>;7089&#x02013;95. [<a href="https://pubmed.ncbi.nlm.nih.gov/27923827" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Preclinical+evidence+that+3&#x02019;-Deoxy-3&#x02019;-[18F]Fluorothymidine+PET+can+visualize+recovery+of+hematopoiesis+after+gemcitabine+chemotherapy&amp;author=S+Schelhaas&amp;author=A+Held&amp;author=N+B&#x020ac;aumer&amp;author=T+Viel&amp;author=S+Hermann&amp;volume=76&amp;publication_year=2016&amp;pages=7089-95&amp;pmid=27923827&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="mixed-citation">Juan G, Bush TL, Ma C, Manoukian R, Chung G, Hawkins JM, et al. 
<span class="ref-title">AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues</span>. <span class="ref-journal">Journal of Translational Medicine</span>. 2014;<span class="ref-vol">12</span>:307. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4221688/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25367255" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Translational+Medicine&amp;title=AMG+900,+a+potent+inhibitor+of+aurora+kinases+causes+pharmacodynamic+changes+in+p-Histone+H3+immunoreactivity+in+human+tumor+xenografts+and+proliferating+mouse+tissues&amp;author=G+Juan&amp;author=TL+Bush&amp;author=C+Ma&amp;author=R+Manoukian&amp;author=G+Chung&amp;volume=12&amp;publication_year=2014&amp;pages=307&amp;pmid=25367255&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="mixed-citation">Shagisultanova E, Dunbrack RL, Golemis EA. <span class="ref-title">Issues in interpreting the in vivo activity of Aurora-A inhibitors</span>. <span class="ref-journal">Expert Opin Ther Targets</span>
2015:<span class="ref-vol">19</span>: 187&#x02013;200. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4294965/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25384454" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Ther+Targets&amp;title=Issues+in+interpreting+the+in+vivo+activity+of+Aurora-A+inhibitors&amp;author=E+Shagisultanova&amp;author=RL+Dunbrack&amp;author=EA+Golemis&amp;volume=19&amp;publication_year=2015&amp;pages=187-200&amp;pmid=25384454&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="mixed-citation">Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM
et al. 
<span class="ref-title">Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study</span>. <span class="ref-journal">Blood</span>
1997;<span class="ref-vol">89</span>:3323&#x02013;9. [<a href="https://pubmed.ncbi.nlm.nih.gov/9129038" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Acute+myeloid+leukemia+in+the+elderly:+assessment+of+multidrug+resistance+(MDR1)+and+cytogenetics+distinguishes+biologic+subgroups+with+remarkably+distinct+responses+to+standard+chemotherapy.+A+Southwest+Oncology+Group+study&amp;author=CP+Leith&amp;author=KJ+Kopecky&amp;author=J+Godwin&amp;author=T+McConnell&amp;author=ML+Slovak&amp;volume=89&amp;publication_year=1997&amp;pages=3323-9&amp;pmid=9129038&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R44">44. <span class="mixed-citation">Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. 
<span class="ref-title">All-trans-retinoic acid in acute promyelocytic leukemia</span>. <span class="ref-journal">N Engl J Med</span>
1997;<span class="ref-vol">337</span>:1021&#x02013;28. [<a href="https://pubmed.ncbi.nlm.nih.gov/9321529" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=All-trans-retinoic+acid+in+acute+promyelocytic+leukemia&amp;author=MS+Tallman&amp;author=JW+Andersen&amp;author=CA+Schiffer&amp;author=FR+Appelbaum&amp;author=JH+Feusner&amp;volume=337&amp;publication_year=1997&amp;pages=1021-28&amp;pmid=9321529&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R45">45. <span class="mixed-citation">Mitchison TJ. <span class="ref-title">The proliferation rate paradox in antimitotic chemotherapy</span>. <span class="ref-journal">Mol Biol Cell</span>
2012;<span class="ref-vol">23</span>:1&#x02013;6. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3248889/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22210845" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Biol+Cell&amp;title=The+proliferation+rate+paradox+in+antimitotic+chemotherapy&amp;author=TJ+Mitchison&amp;volume=23&amp;publication_year=2012&amp;pages=1-6&amp;pmid=22210845&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R46">46. <span class="mixed-citation">Floc&#x02019;h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, et al. 
<span class="ref-title">Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles</span>. <span class="ref-journal">Mol Cancer Ther</span>
2017;<span class="ref-vol">16</span>:1031&#x02013;40. [<a href="https://pubmed.ncbi.nlm.nih.gov/28292940" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Optimizing+Therapeutic+Effect+of+Aurora+B+Inhibition+in+Acute+Myeloid+Leukemia+with+AZD2811+Nanoparticles&amp;author=N+Floc&#x02019;h&amp;author=S+Ashton&amp;author=P+Taylor&amp;author=D+Trueman&amp;author=E+Harris&amp;volume=16&amp;publication_year=2017&amp;pages=1031-40&amp;pmid=28292940&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R47">47. <span class="mixed-citation">Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. <span class="ref-title">[18F] FLT-PET in oncology: current status and opportunities</span>. <span class="ref-journal">Eur J Nucl Med Mol Imaging</span>
2004;<span class="ref-vol">31</span>:1659&#x02013;72. [<a href="https://pubmed.ncbi.nlm.nih.gov/15565331" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Nucl+Med+Mol+Imaging&amp;title=[18F]+FLT-PET+in+oncology:+current+status+and+opportunities&amp;author=LB+Been&amp;author=AJ+Suurmeijer&amp;author=DC+Cobben&amp;author=PL+Jager&amp;author=HJ+Hoekstra&amp;volume=31&amp;publication_year=2004&amp;pages=1659-72&amp;pmid=15565331&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R48">48. <span class="mixed-citation">Sampath D, Rao VA, Plunkett W. <span class="ref-title">Mechanisms of apoptosis induction by nucleoside analogs</span>. <span class="ref-journal">Oncogene</span>
2003;<span class="ref-vol">22</span>:9063&#x02013;74. [<a href="https://pubmed.ncbi.nlm.nih.gov/14663485" ref="reftype=pubmed&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Mechanisms+of+apoptosis+induction+by+nucleoside+analogs&amp;author=D+Sampath&amp;author=VA+Rao&amp;author=W+Plunkett&amp;volume=22&amp;publication_year=2003&amp;pages=9063-74&amp;pmid=14663485&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6279493&amp;issue-id=325175&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC6279493/pdf/nihms-1508729.pdf" class="int-view">PDF (1.7M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/6279493/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/6279493/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="6279493" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6279493%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="CBM7JBHrDuaa8yCEh6EG67CGExuQqBhA0Ek0E3cjA79Fc6IN2aZQWGSgmJXs5tH6">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6279493%2F&amp;text=Dual%20targeting%20of%20aurora%20kinases%20with%20AMG%20900%20exhibits%20potent%20preclinical%20activity%20against%20acute%20myeloid%20leukemia%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6279493%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279493/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC6279493/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/30266802/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC6279493/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/30266802/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC6279493/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/6279493/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC6279493/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
